New hope for rare liver disease: experimental drug CS0159 enters Mid-Stage trial
NCT ID NCT05896137
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests an experimental drug called CS0159 in 50 people with primary sclerosing cholangitis (PSC), a rare liver disease. The study has a 12-week placebo-controlled phase followed by a 40-week open-label period to check safety and how well the drug works. Researchers will measure side effects and changes in liver enzyme levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CS0159 (oral drug)
What this could lead to
If successful, this could point toward a new treatment to control primary sclerosing cholangitis and reduce liver damage.
What could go wrong
This is an early Phase 2 trial with only 50 participants, so results may not apply broadly. The drug may not improve outcomes or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SCLEROSING CHOLANGITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Friendship Hospital, Captail Medcial University
Beijing, Beijing Municipality, 100050, China
-
Beijing YouAn Hostital, Captial Medical University
Beijing, Beijing Municipality, 100069, China
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
-
Qilu Hospital of Shandong University
Jinan, Shandong, China
-
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200120, China
-
Shaoyifu Hospital of Zhejiang University Medical
Hangzhou, Zhejiang, 310000, China
-
The First Affiliated Hospital of USTC Anhui Provincial Hospital
Hefei, Anhui, China
-
The First Affiliated Hospital,Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
-
The First Bethune Hospital of Jilin University
Changchun, Jilin, China
-
The Seconed Xiangya Hospital of Central South University
Changsha, Hunan, 410011, China
-
Wuhan Union Hospital of China
Wuhan, Hubei, 430022, China